title: [Treatment and prognostic factors of stage I and II non-Hodgkin's lymphoma].
abstract: In order to assess prognostic factors and therapeutic methods, 104 patients (aged 6 to 89; mean age 57.4; male 68, female 36; stage: I 45, II 59) with clinical stages I and II non-Hodgkin's lymphoma treated at our department between 1977 and 1991 were reviewed. Factors, such as sex, age, clinical stage, primary site, presence of general symptoms, pathology, tumor size, LDH and therapeutic methods (radiotherapy alone; initial radiotherapy plus chemotherapy; initial chemotherapy plus radiotherapy) were calculated by univariated analysis to determine important factors influencing the survival. The survival of patients with symptoms and large tumors (more than 70 mm) was shorter than that of those without symptoms and with small tumors (5 years survival: symptom B 17.9%, A 68.2%, p < 0.001; tumor more than 70 mm 44.0%, less than 70 mm 67.1%, p < 0.05). Regarding therapeutic methods, radiotherapy alone achieved a 5-year survival rate of 37.1%; initial radiotherapy plus chemotherapy had 64.6% and initial chemotherapy plus radiotherapy 78.5%, but a significant difference was noticed only between radiotherapy alone and initial chemotherapy plus radiotherapy (p < 0.001). These results suggest that important factors influencing the survival are presence of general symptoms, tumor size and therapeutic methods.
authors.affiliation: Department of Radiology, Asahikawa Medical College, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Mineta
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
authors.forename: K
authors.initials: K
authors.lastname: Hayasaka
authors.forename: T
authors.initials: T
authors.lastname: Takashio
authors.forename: Y
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Aburano
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate